To the best of our knowledge, this work introduces the first selective small molecular weight inhibitor of the SMURF1 HECT domain with demonstrated efficacy in animal models and suitable drug-like properties, offering an urgently needed therapeutic option for PAH and potentially other diseases involving SMURF1. Here, SMURF1 is linked to pulmonary arterial hypertension.